Data from two large, open-label studies show patients experienced one-year survival rates above 50 percent when treated with ALIMTA(R) (pemetrexed for injection) or ALIMTA-based regimens for malignant pleural mesothelioma (MPM) in both a first-line and second-line setting. : http://www.asbestos-lawyers.it/data_affirm_benefit_of_alimta_r_pemetrexed_for_injection_for_patients_with_malignant_pleural_mesothelioma_press_trust_of_india_-Nbgkgglzb.html